June 30, 2020 / 4:25 PM / 5 days ago

BRIEF-Genkyotex Announces Dosing Of First Subjects In Its Phase 1 Study With High-Dose Setanaxib

June 30 (Reuters) - GenKyoTex SA:

* GENKYOTEX ANNOUNCES THE DOSING OF THE FIRST SUBJECTS IN ITS PHASE 1 STUDY WITH HIGH-DOSE SETANAXIB

* STUDY AIMS TO SUPPORT USE OF HIGH-DOSE SETANAXIB IN FUTURE CLINICAL TRIALS, INCLUDING PIVOTAL REGISTRATION TRIAL OF SETANAXIB IN PRIMARY BILIARY CHOLANGITIS (PBC)

* THIS PHASE 1 STUDY WILL EVALUATE SETANAXIB ADMINISTERED AT DOSES UP TO 1,600 MG/DAY

* GENKYOTEX ANTICIPATES SUPERIOR EFFICACY IN PBC WITH A HIGHER DOSE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below